Andrea Cara

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9559196/publications.pdf

Version: 2024-02-01

92 papers 4,628 citations

30 h-index 65 g-index

99 all docs 99 docs citations 99 times ranked 4587 citing authors

#	Article	IF	CITATIONS
1	The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection. Nature Medicine, 1996, 2, 1244-1247.	30.7	524
2	Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science, 1994, 266, 801-805.	12.6	341
3	Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 8925-8928.	7.1	316
4	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nature Communications, 2021, 12, 2670.	12.8	297
5	Renal Epithelium Is a Previously Unrecognized Site of HIV-1 Infection. Journal of the American Society of Nephrology: JASN, 2000, 11, 2079-2087.	6.1	287
6	Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nature Medicine, 2002, 8, 522-526.	30.7	286
7	Human T-Cell Lymphotropic/Leukemia Virus Type 1 Tax Abrogates p53-Induced Cell Cycle Arrest and Apoptosis through Its CREB/ATF Functional Domain. Journal of Virology, 1998, 72, 8852-8860.	3.4	168
8	Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nature Communications, $2021, 12, 6871$.	12.8	147
9	HIV-1 Nef Induces Proliferation and Anchorage-Independent Growth in Podocytes. Journal of the American Society of Nephrology: JASN, 2002, 13, 1806-1815.	6.1	137
10	Novel Integrase-Defective Lentiviral Episomal Vectors for Gene Transfer. Human Gene Therapy, 2004, 15, 361-372.	2.7	132
11	Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Medicine, 1995, 1, 667-673.	30.7	99
12	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. Molecular Therapy, 2007, 15, 1716-1723.	8.2	79
13	Human Immunodeficiency Virus-1 Induces Loss of Contact Inhibition in Podocytes. Journal of the American Society of Nephrology: JASN, 2001, 12, 1677-1684.	6.1	78
14	The impact of telomere erosion on memory CD8+ T cells in patients with X-linked lymphoproliferative syndrome. Mechanisms of Ageing and Development, 2005, 126, 855-865.	4.6	72
15	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 2004, 22, 3258-3269.	3.8	70
16	TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells. Oncogene, 2015, 34, 5163-5174.	5.9	69
17	HIV-1 Extrachromosomal 2-LTR Circular DNA Is Long-Lived in Human Macrophages. Viral Immunology, 2005, 18, 190-196.	1.3	65
18	Self-Limiting, Cell Type-Dependent Replication of an Integrase-Defective Human Immunodeficiency Virus Type 1 in Human Primary Macrophages but Not T Lymphocytes. Virology, 1995, 208, 242-248.	2.4	59

#	Article	IF	Citations
19	HIV-1 Protein Expression from Synthetic Circles of DNA Mimicking the Extrachromosomal Forms of Viral DNA. Journal of Biological Chemistry, 1996, 271, 5393-5397.	3.4	57
20	Multicolor Bioluminescence Boosts Malaria Research: Quantitative Dual-Color Assay and Single-Cell Imaging in <i>Plasmodium falciparum</i> Parasites. Analytical Chemistry, 2014, 86, 8814-8821.	6.5	54
21	<i>Macaca mulatta</i> , <i>fascicularis</i> and <i>nemestrina</i> in AIDS vaccine development. Expert Review of Vaccines, 2008, 7, 1419-1434.	4.4	45
22	Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine, 2009, 27, 4622-4629.	3.8	41
23	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	8.2	41
24	New insight on the role of extrachromosomal retroviral DNA. Leukemia, 1997, 11, 1395-1399.	7.2	40
25	Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. International Journal of Cancer, 2013, 132, 335-344.	5.1	38
26	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1472-1481.	3 . 6	36
27	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. DNA and Cell Biology, 2002, 21, 599-610.	1.9	35
28	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responsesin Vitroandin Vivo. Viral Immunology, 2006, 19, 690-701.	1.3	35
29	Endogenous CCL2 neutralization restricts HIV-1 replication in primary human macrophages by inhibiting viral DNA accumulation. Retrovirology, 2015, 12, 4.	2.0	35
30	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8 ⁺ T Cells. Human Gene Therapy, 2010, 21, 1029-1035.	2.7	32
31	Renal epithelial cells produce and spread HIV-1 via T-cell contact. Aids, 2014, 28, 2345-2353.	2.2	32
32	Circular Viral DNA and Anomalous Junction Sequence in PBMC of HIV-Infected Individuals with No Detectable Plasma HIV RNA. Virology, 2002, 292, 1-5.	2.4	31
33	Retroviral E-DNA: persistence and gene expression in nondividing immune cells. Journal of Leukocyte Biology, 2006, 80, 1013-1017.	3.3	31
34	Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. Frontiers in Immunology, 2018, 9, 171.	4.8	31
35	Level of Human Immunodeficiency Virus DNA in Peripheral Blood Mononuclear Cells Correlates with Efficacy of Antiretroviral Therapy. Journal of Clinical Microbiology, 1999, 37, 2361-2365.	3.9	31
36	Effect of Tissue Processing on the Ability to Recover Nucleic Acid from Specific Renal Tissue Compartments by Laser Capture Microdissection. Nephron Experimental Nephrology, 2001, 9, 229-234.	2.2	30

#	Article	IF	CITATIONS
37	Superfibronectin, a Multimeric Form of Fibronectin, Increases HIV Infection of Primary CD4+T Lymphocytes. Journal of Immunology, 2000, 164, 3236-3245.	0.8	29
38	Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors. Journal of General Virology, 2005, 86, 765-771.	2.9	29
39	Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opinion on Biological Therapy, 2011, 11, 739-750.	3.1	29
40	A high susceptibility to redox imbalance of the transmissible stages of <scp><i>P</i></scp> <i>lasmodium falciparum</i> revealed with a luciferaseâ€based mature gametocyte assay. Molecular Microbiology, 2017, 104, 306-318.	2.5	28
41	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. Journal of General Virology, 2006, 87, 1625-1634.	2.9	26
42	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	4.4	26
43	Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses. Cell Reports, 2019, 26, 1242-1257.e7.	6.4	23
44	Human Immunodeficiency Virus Type 1 (HIV-1) Integration: a Potential Target for Microbicides To Prevent Cell-Free or Cell-Associated HIV-1 Infection. Antimicrobial Agents and Chemotherapy, 2008, 52, 2544-2554.	3.2	22
45	Inhibition of HIV-1 replication by combined expression of gag dominant negative mutant and a human ribonuclease in a tightly controlled HIV-1 inducible vector. Gene Therapy, 1998, 5, 65-75.	4.5	21
46	Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. Retrovirology, 2012, 9, 69.	2.0	21
47	HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein. Retrovirology, 2007, 4, 17.	2.0	20
48	Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	20
49	Identification of HIV-1 genitourinary tract compartmentalization by analyzing the env gene sequences in urine. Aids, 2015, 29, 1651-1657.	2.2	20
50	Development of a Human Immunodeficiency Virus Vector-Based, Single-Cycle Assay for Evaluation of Anti-Integrase Compounds. Antimicrobial Agents and Chemotherapy, 2006, 50, 3407-3417.	3.2	18
51	Toward Integrase Defective Lentiviral Vectors for Genetic Immunization. Current HIV Research, 2010, 8, 274-281.	0.5	18
52	Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity. Molecular Therapy - Methods and Clinical Development, 2020, 17, 532-544.	4.1	18
53	Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant î"V2 Env. Microbes and Infection, 2005, 7, 1392-1399.	1.9	17
54	Conditionally replicating lentiviral-hybrid episomal vectors for suicide gene therapy. Antiviral Research, 2008, 80, 288-294.	4.1	17

#	Article	IF	Citations
55	Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine, 2008, 26, 3268-3276.	3.8	17
56	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine, 2011, 29, 3465-3475.	3.8	17
57	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. Viruses, 2021, 13, 355.	3.3	17
58	Mucosal Immunization with Integrase-Defective Lentiviral Vectors Protects against Influenza Virus Challenge in Mice. PLoS ONE, 2014, 9, e97270.	2.5	17
59	Neurite outgrowth and cell cycle kinetic changes induced by cis-diamminedichloroplatinum II and retinoic acid in a human neuroblastoma cell line. Cancer Letters, 1990, 52, 101-106.	7.2	16
60	p53 functional impairment and high p21waf1/cip1 expression in human T- cell lymphotropic/leukemia virus type I-transformed T cells. Blood, 1996, 88, 1551-1560.	1.4	16
61	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. Journal of Virological Methods, 2010, 168, 272-276.	2.1	15
62	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology, 2004, 324, 531-539.	2.4	12
63	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. PLoS ONE, 2014, 9, e107377.	2.5	12
64	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	6.0	12
65	Integrase Defective, Nonintegrating Lentiviral Vectors. Methods in Molecular Biology, 2010, 614, 101-110.	0.9	12
66	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. Journal of General Virology, 2006, 87, 3385-3392.	2.9	11
67	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	6.0	11
68	Strong SARS-CoV-2 N-Specific CD8+ T Immunity Induced by Engineered Extracellular Vesicles Associates with Protection from Lethal Infection in Mice. Viruses, 2022, 14, 329.	3.3	11
69	Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors. International Journal of STD and AIDS, 2012, 23, 459-463.	1.1	10
70	Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. Journal of Antimicrobial Chemotherapy, 2013, 68, 193-199.	3.0	10
71	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 17, 418-428.	4.1	10
72	Mild SARS-CoV-2 Infection After Gene Therapy in a Child With Wiskott-Aldrich Syndrome: A Case Report. Frontiers in Immunology, 2020, 11, 603428.	4.8	8

#	Article	IF	CITATIONS
73	UltraViolet SANitizing System for Sterilization of Ambulances Fleets and for Real-Time Monitoring of Their Sterilization Level. International Journal of Environmental Research and Public Health, 2022, 19, 331.	2.6	8
74	HIVâ€1 DNA dynamics and variations in HIVâ€1 DNA protease and reverse transcriptase sequences in multidrugâ€resistant patients during successful raltegravirâ€based therapy. Journal of Medical Virology, 2016, 88, 2115-2124.	5.0	7
75	Seasonal Betacoronavirus Antibodies' Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. Journal of Clinical Immunology, 2022, 42, 448-458.	3.8	7
76	Adhesion of Human Neuroblasts to HIV-1 tat. Pediatric Research, 1995, 38, 792-796.	2.3	6
77	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	1.4	6
78	Characterization of ±-Defensins Plasma Levels in Macaca Fascicularisand Correlations with Virological Parameters during SHIV89.6Pcy11Experimental Infection. AIDS Research and Human Retroviruses, 2007, 23, 287-296.	1.1	6
79	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	4.8	6
80	Analysis of CD4 gene expression in human fetal brain and neuroblasts. Cellular and Molecular Neurobiology, 1992, 12, 131-141.	3.3	4
81	No Evidence of Autoimmune Disorders in Antiretroviral-Experienced HIV-1-Infected Individuals after Long-Term Treatment with Raltegravir. Antiviral Therapy, 2013, 18, 321-327.	1.0	4
82	Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. Viruses, 2020, 12, 1460.	3.3	4
83	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Molecular Therapy - Methods and Clinical Development, 2021, 23, 263-275.	4.1	4
84	Engineering viral promoters for gene transfer to human neuroblasts. Cellular and Molecular Neurobiology, 2000, 20, 409-415.	3.3	3
85	Development of a Novel Screen for Protease Inhibitors. Vaccine Journal, 2001, 8, 437-440.	2.6	3
86	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. Virus Research, 2007, 126, 86-95.	2.2	3
87	Effects of Raltegravir on 2-Long Terminal Repeat Circle Junctions in HIV Type 1 Viremic and Aviremic Patients. AIDS Research and Human Retroviruses, 2013, 29, 1365-1369.	1.1	2
88	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	6.0	2
89	Simian immunodeficiency virus-Vpx as an adjuvant for integrase defective lentiviral vector-based vaccines. Retrovirology, 2012, 9, .	2.0	1
90	Murine Granulocyte–Macrophage Colony-Stimulating Factor Expressed from a Bicistronic Simian Immunodeficiency Virus-Based Integrase-Defective Lentiviral Vector Does Not Enhance T-Cell Responses in Mice. Viral Immunology, 2014, 27, 512-520.	1.3	1

#	Article	lF	CITATIONS
91	Intranasal Administration of Integrase Defective Lentiviral Vectors Expressing mAbs Protects from H5 Influenza Virus Challenge In Vivo. Open Forum Infectious Diseases, 2017, 4, S520-S521.	0.9	1
92	157 Fusion Complexes and CD4-Independent Env for the Induction of Broad Spectrum Neutralizing Antibodies Against HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 65.	2.1	0